Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
  • 0 views
  • 23 Jan, 2021
  • 1 location
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence

NUCs treatment before HCC occurrence. It would be interesting to investigate the incidence of recurrence by switching to tenofovir alafenamide(TAF) after curative treatment of HCC in patients already

  • 0 views
  • 19 Jul, 2021
  • 4 locations
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC

  • 40 views
  • 31 Dec, 2021
  • 33 locations
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination regimen.

  • 0 views
  • 13 Dec, 2021
  • 1 location
TAF to Prevent HBV Reactivation in Cancer Patients

Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for

  • 0 views
  • 11 Jul, 2021
  • 5 locations
Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels

indications by current guidelines. To assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events (hepatocellular carcinoma, liver-related events and death, decompensated liver

  • 0 views
  • 04 Jan, 2022
  • 6 locations
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are potent antiviral agents for hepatitis B virus (HBV) and recommended by the American Association for the Study of

adefovir
antiviral therapy
entecavir
telbivudine
liver disease
  • 0 views
  • 26 Jan, 2021
  • 10 locations
Tenofovir Alafenamide (TAF) in Children and Adolescents With Chronic Hepatitis B Virus Infection

The primary objective of Cohort 1 of this study is to evaluate the safety, tolerability, and antiviral activity (HBV DNA < 20 IU/mL) of tenofovir alafenamide (TAF) 25 mg once daily versus

chronic hepatitis
estimated creatinine clearance
hepatitis b antigen
antiviral drugs
tenofovir
  • 496 views
  • 16 Jan, 2022
  • 103 locations
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

/3TC] or emtricitabine/tenofovir alafenamide [FTC/TAF])

hiv-1 rna measurement
abacavir
antiviral drugs
emtricitabine
dolutegravir
  • 6 views
  • 29 Dec, 2021
  • 52 locations